Ron Cohen, Acorda Therapeutics president & CEO, offers insight on just how much potential his company's multiple sclerosis drug "AMPYRA" has in the pharmaceutical market.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT